Scribe Therapeutics Expands its 2022 Collaboration with Sanofi to Accelerate In Vivo Genetic Therapies for Sickle Cell and Other Genomic Diseases
Shots:
- Scribe will receive $40M up front, ~$1.2B+ upon completion of development & sales milestones along with royalties on net future sales on any products resulting from the collaboration
- Scribe gets an option for development cost sharing, co-promotion & profit and loss sharing in the US on one future program while Sanofi gets an exclusive license to use Scribe’s CRISPR X-Editing (XE) genome editing technologies to develop in vivo therapies, incl. SCD
- The collaboration will combine Scribe’s precisely engineered CRISPR XE technologies & Sanofi’s capabilities in non-viral delivery to develop & manufacture therapies on a global scale & will advance breakthrough genomic medicines for in vivo treatment of SCD and other diseases
Ref: Bussinesswire | Image: Scribe
Related News:- Scribe Collaborated with Prevail to Advance In Vivo CRISPR-based Genetic Therapies for Neurological and Neuromuscular Diseases
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
